The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict WuXi PharmaTech's revenues will grow 14.2% and EPS will drop 0.0%.
The average estimate for revenue is $124.0 million. On the bottom line, the average EPS estimate is $0.31.
Last quarter, WuXi PharmaTech recorded revenue of $125.8 million. GAAP reported sales were 21% higher than the prior-year quarter's $104.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.36. GAAP EPS of $0.30 for Q3 were 25% higher than the prior-year quarter's $0.24 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 36.6%, 240 basis points worse than the prior-year quarter. Operating margin was 17.0%, 440 basis points worse than the prior-year quarter. Net margin was 16.9%, 290 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $498.1 million. The average EPS estimate is $1.32.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 322 members out of 342 rating the stock outperform, and 20 members rating it underperform. Among 78 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 75 give WuXi PharmaTech a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on WuXi PharmaTech is outperform, with an average price target of $18.70.
Looking for alternatives to WuXi PharmaTech? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add WuXi PharmaTech to My Watchlist.